Analyst will focus on royalties defeat and increased costs in Genmab's Q1 report
When Genmab releases its first quarterly report later today, Sydbank analyst Søren Løntoft Hansen will search for news about the arbitration case the firm lost against Janssen and will keep an eye on expenses.
by marketwire, translated by daniel pedersen
Genmab’s cost developments and a lost arbitration case with its partner, Janssen, the pharmaceutical arm of Johnson & Johnson, will be the focus of the Danish biotech firm’s first quarterly report for 2022, which is slated to release later today, Wednesday, after trading closes in Denmark.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab enters agreement on cancer biomarker
For subscribers
Genmab loses royalties case against Janssen
For subscribers
